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The optimal reduced-intensity conditioning (RIC) for patients with acute lymphoblastic leukemia (ALL) 73 
undergoing allogeneic stem cell transplantation (allo-HSCT) remains unclear. We retrospectively 74 
analyzed 417 patients > 45 years with ALL in first complete remission who underwent a matched-sibling 75 
or unrelated allo-HSCT and compared outcomes between fludarabine/busulfan (FLUBU, n=127), 76 
fludarabine/melphalan (FLUMEL, n=190) and fludarabine-TBI (FLUTBI, n=100) conditioning. At 2 years, 77 
there were no differences between the groups in terms of cumulative incidence (CI) of relapse (40% for 78 
FLUBU vs 36% for FLUMEL vs 41% for FLUTBI, p=0.21); transplant-related mortality (TRM) (18% for 79 
FLUBU, 22% for FLUMEL, 14% for FLUTBI, p=0.09); overall survival (OS) (55% for FLUBU, 50% for 80 
FLUMEL, 60% for FLUTBI, p=0.62) or leukemia-free survival (LFS) (43% for FLUBU, 42% for FLUMEL, 45% 81 
for FLUTBI, p=0.99), but GVHD-relapse-free survival (GFRS) was significantly lower in the FLUTBI group 82 
than FLUBU and FLUMEL group (18% vs 35% vs 28%, p=0.02).  However, this difference was lost in the 83 
multivariate analysis when adjusted for the in vivo T-cell depletion. Finally, the FLUMEL regimen was 84 
shown to be an independent risk factor for a higher TRM (HR 1.97, 95% CI 1.05-3.72, p=0.04). We 85 
conclude that the 3 most popular RIC regimens yield similar transplant outcomes.  86 




















Long-term outcomes of older adults with acute lymphoblastic leukemia (ALL) remain poor, with an 106 
estimated 5-year leukemia-free survival (LFS) of approximately 30-40% (1-3). These results have been 107 
obtained with chemotherapy alone and are partly due to the inability of older adults to tolerate 108 
intensive regimens used in pediatric and young adult populations. The use of conventional 109 
myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been shown to 110 
improve survival rates in adults by 45-75% (4,5). However, transplant-related mortality (TRM) after 111 
myeloablative allo-HSCT is substantial, ranging between 33 and 58% (6), increases with age, and is 112 
higher for adults with impaired performance status (7,8). In such patients, reduced intensity 113 
conditioning (RIC) may offer the chance of a potentially curative strategy by obtaining a graft-versus-114 
leukemia effect without the associated toxicities of myeloablative conditioning (MAC). On the other 115 
hand, the risk of relapse after RIC regimens may be greater than that after MAC regimens (8-10).  116 
Although several RIC regimens have been developed over the last decades, their cytotoxic and 117 
immunosuppressive effects are different, and this may influence transplant outcome. However, to date 118 
there have been no large prospective studies comparing outcomes of different RIC regimens in patients 119 
with acute leukemias, and the optimal RIC regimen in allo-HSCT remains unclear.  The most widely used 120 
RIC regimens are fludarabine with intermediate doses of busulfan (6.4 mg/kg), fludarabine with 121 
intermediate doses of melphalan (140 mg/m2) and fludarabine with low-dose total-body irradiation (TBI, 122 
2 Gy). Several retrospective studies have compared these regimens, but with contradictory results 123 
(11,12). This is probably due to small population numbers, different diseases being analyzed together 124 
and neither age limit for enrollment nor dosage of drugs in regimens being fixed. Furthermore, these 125 
studies focused mostly on acute myeloid leukemia and included only small numbers of ALL patients. 126 
We therefore took advantage of the European Society for Blood and Marrow Transplantation (EBMT) 127 
dataset, and retrospectively compared outcomes of these three most popular RIC conditioning regimens 128 
following allo-HSCT from a matched sibling donor or an unrelated donor in a large homogeneous 129 
population of ALL patients aged 45 years or older undergoing transplant in first complete remission 130 





Patients and methods 135 
Study design and data collection  136 
This is a registry based retrospective study. Data were provided and the study design was approved by 137 
the Acute Leukemia Working Party (ALWP) of the EBMT group registry, in accordance with the EBMT 138 
guidelines for retrospective studies. The EBMT is a voluntary working group of more than 600 transplant 139 
centers which are required to report all consecutive stem cell transplantations and follow-ups once a 140 
year. Audits are routinely performed to determine the accuracy of the data. Since 1990, patients have 141 
been able to provide informed consent to authorize the use of their transplant information for research 142 
purposes. The ALWP of the EBMT granted ethical approval for this study.  143 
Patient selection 144 
Patients were selected according to the following criteria: (1) aged 45 years and older at the time of 145 
transplantation, (2) a diagnosis of ALL, with available data on the immunophenotype and Ph-positivity, 146 
(3) in CR1 (4) initial allo-HSCT between 2005 and June 2016, (4) HLA-matched related or unrelated donor 147 
(fully matched or mismatched at one HLA locus), (5) received peripheral blood hematopoietic stem cells 148 
(PBSC), (6) underwent the RIC conditioning regimen. Patients who received a previous allo-HSCT or T-149 
depleted grafts were excluded. Indication for RIC allo-SCT depended on each center’s policy. The RIC 150 
regimen was defined as the use of fludarabine associated with intermediate doses of intravenous 151 
busulfan (FLUBU, busulfan at 6.4 mg/kg), intermediate doses of melphalan (FLUMEL, melphalan at 140 152 
mg/m2) or low-dose total body irradiation (FLUTBI; TBI at 2 Gy).  153 
Endpoints and definitions 154 
The primary endpoint was overall survival (OS). Secondary endpoints were cumulative incidences (CI) of 155 
relapse, transplant-related mortality (TRM), acute and chronic graft-versus-host disease (GVHD), 156 
leukemia-free survival (LFS) and graft-versus-host disease free, relapse-free survival (GRFS). Acute and 157 
chronic GVHD were graded according to previously published criteria (13,14). OS was defined as the 158 
probability of survival, TRM as death without evidence of relapse, LFS as survival with no evidence of 159 
relapse or disease progression. GRFS was defined as survival with no previous grade III–IV acute GVHD, 160 
no severe chronic GVHD and no relapse.  161 
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 162 
Statistical analysis 163 
The main patient characteristics were compared using the Mann-Whitney test for quantitative variables 164 
and chi-square test or Fisher’s exact test for categorical variables. Probabilities of OS, LFS and GRFS were 165 
estimated using the Kaplan-Meier method, and the differences between groups were compared using 166 
the log-rank test. GVHD, relapse and TRM were calculated using the cumulative incidence method and 167 
analyzed in a time-dependent fashion. Differences between groups were compared using the Gray’s 168 
test. For acute and chronic GVHD or relapse, death of the patient was considered as a competing risk of 169 
the event. For TRM, the competing event was relapse. Factors differing between the groups in terms of 170 
distribution and factors significantly associated with the outcome were included in the multivariate 171 
analysis. Multivariate analyses were performed using the Cox proportional-hazard model. All tests were 172 
two-sided and P values < 0.05 were considered as indicating a statistically significant association. 173 
Analyses were performed using the R statistical software version 3.2.3 (available online at 174 
http://www.R-project.org). 175 
 176 
Results  177 
 178 
Patient characteristics 179 
A total of 417 patients was included in this study; 127 patients in the FLUBU group, 190 patients in the 180 
FLUMEL group and 100 patients in the FLUTBI group. Patient characteristics of each group are 181 
summarized in Table 1. The median follow-up of patients was significantly longer (p=0.001) in the 182 
FLUTBI group (51 months, range, 34-69) than in the FLUBU group (35 months, range, 25-45) and FLUMEL 183 
group (23 months, range, 20-26). Patients in the FLUBU group were significantly older (median 59 years, 184 
range 45-71) than patients in the FLUMEL (median 54 years, range 45-74) and the FLUTBI (median 57 185 
years, range 45-72) groups, (p=0.001). Incidence of Ph+ ALL was lower in the FLUMEL group compared 186 
to FLUBU or FLUTBI groups (52% vs 69%, p<0.001). Most patients in the FLUBU group received ATG  187 
(88%), while most of the FLUMEL patients received Campath (71%) as GVHD prophylaxis. Only 12% of 188 
the patients received in vivo T-cell depletion in the FLUTBI group (11 ATG and 1 Campath). The rest of 189 





OS, LFS, relapse and TRM 194 
At 2 years after transplantation, there was no significant differences in OS between the groups (Figure 195 
1A, p=0.62) – namely; OS in the FLUBU group was 55%, (95%CI 45-65); 50% in the FLUMEL group (95%CI 196 
42-59); and 60% in the FLUTBI group  (95%CI 49-70). There was also no significant difference in LFS 197 
between the groups (p=0.99);  (Figure 1B); 43% in the FLUBU group (95%CI 33-52); 42% in the FLUMEL 198 
group (95%CI 34-51) and 45% in the  FLUTBI group (95%CI 35-56). Furthermore, there was no significant 199 
difference in the CI of relapse between the groups as shown in Figure 1C (p=0.21); it was 40 % in the 200 
FLUBU group (95%CI 30-49) at a median of 4.8 months (range, 1-49); 36% in the FLUMEL group (95%CI 201 
28-44) at a median of 6 months (range, 2-32); and 41% in the FLUTBI group (95%CI 30-51) at a median of 202 
3.7 months (range, 1-.31). Finally, TRM was also comparable between the groups (p=0.09) (Figure 1D); 203 
18% in the  FLUBU group (95%CI 11-26); 22% in the FLUMEL group (95%CI 16-29) and 14% in the FLUTBI 204 
group (95%CI, 8-22). The most frequent cause of death in all groups was relapse; 42% in the FLUBU 205 
group, 41% in the FLUMEL group and 60% in the FLUTBI group followed by GVHD; 28% in the FLUBU 206 
group, 14% in the FLUMEL group and 16% in the FLUTBI group. The CI of death associated with infection 207 
was highest in the FLUMEL group (11%, 95%CI, 7-16), followed by the FLUBU group (7%, 95% CI, 3-13) 208 
and lowest in the FLUTBI group (6%, 95% CI, 2-12). 209 
 210 
Acute and chronic GVHD, GRFS 211 
All groups had a similar CI of grade II-IV acute GVHD; 23% in the FLUBU group (95%CI 16-31), 27% in the 212 
FLUMEL group (95%CI 20-33) and 32% in the FLUTBI group (95%CI 23-42) (p=0.33). However, the CI of 213 
extensive chronic GVHD was significantly higher in the FLUTBI group (39%, 95%CI 29-50) in comparison 214 
to FLUBU (16%, 95%CI 9-23) and FLUMEL group (12%, 95%CI 7-18) (p=0.001) (Figure 1E). This difference 215 
resulted  in significantly lower GFRS in the FLUTBI group (18%, 95%CI 10-26) compared to the FLUBU 216 
(35%, 95%CI 25-44) and the FLUMEL groups (28%, 95%CI 20-36) (p=0.02) (Figure 1F).  217 
 218 
Multivariate analysis 219 
The results of multivariate analysis are shown in Table 2. On adjustment for patient-, disease- and 220 
transplant related-factors that were different among groups, a worse OS was associated only with older 221 
age (hazard ratio (HR) 1.56, 95% CI 1.21-2.03, p=0.0007) and female gender of patient (HR 0.67, 95% CI 222 
0.49-0.93, p=0.01). Furthermore, decreased LFS was associated only with older age of patient (HR 1.57, 223 
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95% CI 1.23-2.00, p=0.0003). The CI of relapse was increased in older patients (HR 1.4, 95% CI 1.05-1.87, 224 
p=0.02) and CMV positive patients. (HR 0.66, 95% CI 0.45-0.97, p=0.03). Finally, the TRM was higher in 225 
the FLUMEL group (HR 1.97, 95% CI 1.05-3.71, p=0.04), as well as in older patients (HR 2.08, 95% CI 1.37-226 
3.15, p=0.0006) and patients receiving a transplant from an unrelated donor (HR 2.22, 95% CI 1.23-4.01, 227 
p=0.008).  On multivariate analysis, there were no differences in CI of chronic GVHD and GRFS between 228 
the 3 conditioning regimens when adjusting for the use of in vivo T-cell depletion.  The CI of chronic 229 
GVHD was higher with the use of unrelated donors (HR 2.00, 95% CI 1.33-3.02, p=0.0008), while lower 230 
for transplants from CMV positive donors (HR 0.66, 95% CI 0.45-0.98, p=0.04) and with the use of T-cell 231 
depletion (HR 0.44, 95% CI 0.27-0.73, p=0.001). Finally, the only significant factor associated with lower 232 
GRFS was older age of the patient (HR 1.53, 95% CI 1.23-1.90, p=0.0001). 233 
 234 
Discussion 235 
To our knowledge, this is the first study comparing outcomes of the most used RIC conditioning 236 
regimens in adults with ALL. We compared RIC allo-HSCT after FLUBU, FLUMEL and FLUTBI conditioning 237 
in 417 ALL patients in CR1 and found similar transplantation outcomes in terms of OS, LFS and relapse. 238 
However, lack of in-vivo T-cell depletion with the FLUTBI regimen yielded more cGVHD and a lower 239 
GRFS, while FLUMEL emerged as an independent predictor of TRM in the multivariate analysis.  240 
Allo-HSCT in CR1 is still often offered to older adults with ALL who are not treated with pediatric-241 
inspired regimens. These patients are usually not eligible for MAC either, therefore many older adults 242 
standardly undergo RIC allo-HSCT. This strategy is supported by several large retrospective studies, 243 
which compared RIC vs MAC allo-HSCT in ALL patients and found a reduction of TRM in the RIC group 244 
(7,8,15-17). Unfortunately, this did not translate into a significant difference in OS, due to the higher risk 245 
of relapse in the RIC group. However, these studies included heterogeneous patient populations and a 246 
wide variety of conditioning regimens which could confound true differences between conditioning 247 
regimen intensity. This also raises the question of whether the choice of a RIC regimen could impact 248 
long-term leukemic control differently and improve outcomes.  249 
So far, the answer to this question has been based mostly on single institution studies reporting their 250 
outcomes with RIC allo-HSCT (18-22). These studies were rather heterogeneous, included only a small 251 
number of ALL patients or had looked at a variety of conditioning regimens, making results difficult to 252 
interpret. However, two of these studies are worth mentioning as they reported impressive outcomes, 253 
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both with FLUMEL conditioning. The first study from the City of Hope group reported a 2-year OS of 254 
61.5% in 24 ALL patients aged over 50 years, with compromised organ function or prior allo-HSCT, while 255 
the Korean group reported a 3-year OS of 64% in 37 ALL patients with similar characteristics (18, 19). 256 
Interestingly, this is in concordance with the results from a prospective UK NCRI UKALL14 study, 257 
reporting a 2-year OS of 63% in 186 patients aged 40 years or older after a FLU-MEL-alemtuzumab 258 
conditioning (23). We, on the other hand, analyzed a similarly large FLUMEL group of 190 patients and 259 
found a 2-year OS of 50%, lower than OS in the FLUTBI (60%) and FLUBU group (55%) (p=0.62). Better 260 
outcomes in previous studies are probably related to more uniformity in terms of conditions and better 261 
selection of patients. 262 
Previous retrospective comparisons between different RIC regimens were done mostly between 263 
FLUMEL and FLUBU conditioning and almost exclusively in AML patients (24,25).  In these large 264 
cooperative group studies, relapse incidence was lower in FLUMEL conditioning, but again with 265 
significantly higher TRM which led to similar OS in comparison to the FLUBU group. The only available 266 
previous study including ALL patients that has compared RIC regimens is a subgroup analysis of the MAC 267 
and RIC allo-HSCT comparison done by ALWP (8). Mohty et al. analyzed 43 FLUTBI, 23 FLUBU and 25 268 
FLUMEL allo-HSCT in the RIC subgroup and reported comparable TRM and relapse at 2 years (23 vs. 18 269 
vs. 23%, respectively for TRM, and 55 vs. 45 vs. 48%, respectively for relapse, p = NS). The incidences of 270 
TRM were comparable in our study in the univariate analysis (14% vs 18% vs 22% in FLUTBI vs FLUBU vs 271 
FLUMEL, respectively, p=0.09) but FLUMEL conditioning emerged as a risk factor for higher TRM in the 272 
multivariate analysis.  273 
One criticism of RIC regimens is that many of them do not include TBI, which is thought to reduce the 274 
risk of CNS relapse in ALL (26). This finding is mostly based on MAC and RIC comparisons, where TBI is 275 
usually added to MAC regimens (16, 26). Moreover, a recent large CIBMTR study comparing 276 
myeloablative TBI- and busulfan-based regimens confirmed a protective role of TBI for relapse in a 277 
multivariate analysis (27). Furthermore, a multi-centric study coordinated by the Fred Hutchinson 278 
Cancer Research Center evaluated a FLUTBI RIC regimen in patients older than 50 years, with 279 
comorbidities or prior transplantation and found a remarkable 3-year OS of 62% for patients in CR1 with 280 
relapse ranging from 15% to 32% depending of the Ph+ status (20). This contrasts with our study where 281 
the addition of TBI did not provide better anti-leukemic control since there was no significant difference 282 
in relapse incidence between the FLUTBI group in comparison to FLUBU and FLUMEL groups (41% vs 283 
40% vs 36%, p=0.21). However, the low dose of TBI used in this study (2Gy) may have been insufficient 284 
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to protect against CNS relapse and also we have previously shown that there is wide variation in TBI 285 
delivery among the centers which leads to potential obstacles when analyzing TBI data (28,29). 286 
PBSC is a common source of stem cells in RIC allo-HSCT and all patients in our study received PBSC. 287 
Previous data comparing BM and PBSC in ALL RIC patients are lacking and the only data available are 288 
from the AML setting or from analysis of AML and ALL together, with contradictory results. A large 289 
Centre for International Blood and Marrow Transplant Research (CIBMTR) study in AML patients found 290 
no differences between BM and PBSC outcomes in RIC allo-HSCT (30). On the contrary, a previous EBMT 291 
study of RIC-allo HSCT in AML and ALL patients, found higher OS, LFS and relapse incidence but at the 292 
expanse of more chronic GVHD after the use of PBSC compared to BM (31).  In our study, the only 293 
significant difference between RIC regimens was found in the incidence of chronic GVHD (significantly 294 
higher in the FLUTBI compared to FLUBU and FLUMEL group; (39% vs 16% vs 12%, p=0.001). This led to a 295 
significantly lower GRFS in the FLUTBI group but the difference was lost on multivariate analysis when 296 
adjusted for the use of ATG or Campath, traditionally used in the FLUBU and FLUMEL conditioning. Most 297 
of the patients in our study who received the FLUTBI regimen (88%) did not receive ATG or Campath, 298 
and this highlights the importance of in-vivo T-cell depletion in RIC regimens, particularly when PBSCs 299 
are used.  300 
It is generally accepted that old age itself is not a contraindication for RIC allo-HSCT in patients with 301 
good performance status. However, large registry studies have shown that, when stratified by age, 302 
patients older than 66 years have higher rates of TRM and decreased OS (32). Of course, the older 303 
population also has a worse performance status and more comorbidities which makes it difficult to 304 
discern whether age or performance status contribute more to poorer outcomes. Nevertheless, in our 305 
study increasing age emerged as the main risk factor for worse outcomes; it independently predicted 306 
higher rates of TRM and relapse and lower OS, LFS and GRFS. Therefore, our results support the finding 307 
that in older adults, age may still modify the impact of poor performance status, and transplant, even 308 
with RIC, should be undertaken with caution.  309 
Despite comparable outcomes between RIC regimens, the outcomes reported in our study are still 310 
unsatisfactory, with comparable LFS of less than 50% in all groups (43% in FLUBU vs 42% in FLUMEL vs 311 
45% in FLUTBI, p=0.99).  This highlights the importance of developing strategies for preventing relapse 312 
after allo-HSCT.  Minimal residual disease (MRD) has been shown to be the strongest predictor of 313 
outcome after allo-HSCT (33-37). Strategies to improve allo-HSCT outcome in MRD-positive patients 314 
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include pre-transplant elimination of MRD with potent new drugs such as blinatumomab (38), pre-315 
transplant adjustment of ATG doses based on lymphocyte counts (39), as well as post-transplant pre-316 
emptive donor-lymphocyte infusion (DLI) (40). A step further is the prevention of relapse in MRD-317 
negative high-risk patients and includes tyrosine kinase inhibitor (TKI) maintenance therapy in Ph-318 
positive (41-43), or prophylactic DLI in Ph-negative patients. In relapsed patients, major improvements 319 
have been made with bispecific and drug-conjugated antibodies (blinatumomab and inotuzumab 320 
ozogamicin), while exciting new strategies include genetically-enginereed T-lymphocytes -  the chimeric 321 
antigen receptor T-cells (CAR-T cells) (44-46).  322 
Our analysis has some limitations, mainly due to its retrospective design and some significant 323 
differences between populations’ characteristics. Furthermore, it was not possible to provide the details 324 
of comorbidities nor further information on MRD in patients before transplant, which could have 325 
affected transplant outcomes. Nevertheless, this is the largest study of ALL patients receiving RIC allo-326 
HSCT reported so far, leading to some important conclusions.   327 
In summary, the three most popular RIC  preparative regimens  (FLUBU, FLUMEL and FLUTBI) yield 328 
similar transplantation outcomes in adults with ALL. However, FLUMEL conditioning seems to be 329 
associated with higher transplant-related toxicity, while more chronic GVHD in the FLUTBI group is 330 
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  TABLES 570 
   Table 1. Study population characteristics 571 





Figure 1. Overall survival at 24 months (A); 55% (95%CI 45-65) in the FLUBU group; 50% (95%CI 42-59) 577 
in the FLUMEL group; and 60% (95%CI 49-70) in the FLUTBI group (p=0.62);  578 
Leukemia-free survival at 24 months (B); 43% (95%CI 33-52) in the FLUBU group; 42% (95%CI 34-51) 579 
in the FLUMEL group and 45% (95%CI 35-56) in the FLUTBI group (p=0.99);  580 
Cumulative incidence of relapse at 24 months (C); 40% (95%CI 30-49) in the FLUBU group; 36% (95%CI 581 
28-44) in the FLUMEL group; and 41% (95%CI 30-51) in the FLUTBI group (p=0.21);   582 
Cumulative incidence of transplant-related mortality (D); 18% (95%CI 11-26) in the FLUBU group; 22% 583 
(95%CI 16-29) in the FLUMEL group and 14% (95%CI, 8-22) in the FLUTBI group (p=0.09);  584 
Cumulative incidence of extensive chronic GVHD (E); 16% (95%CI 9-23) in the FLUBU group, 12% 585 
(95%CI 7-18) in the FLUMEL group and 39%, (95%CI 29-50) in the FLUTBI group (p=0.001). 586 
GVHD-free-relapse-free survival at 24 months (F); 35% (95%CI 25-44) in the FLUBU group; 28% (95%CI 587 












n=100 p value 
Patient age 
median (range) 59 (45-71) 54 (45-74) 57 (45-72) <0.001












diagnosis to Tx in 
months,
median (range)
6 (3-17) 6 (1-18) 6 (3-18)
0.17
Diagnosis
B Ph-neg ALL 31 (24% ) 48 (25% ) 23 (23% )
B Ph-pos ALL 88 (69% ) 98 (52% ) 66 (66% )
T ALL 8 (6% ) 44 (23% ) 11 (11% ) <0.001
Donor
Matched sibling 56 (49% ) 71 (51% ) 50 (54% )
Unrelated 10/10 45 (40% ) 52 (38% ) 32 (35% )
Unrelated 9/10 12 (11% ) 15 (11% ) 10 (11% )
missing 14 52 8 0.97
Karnofsky score
<90 37 (31% ) 42 (24% ) 32 (39% )
>=90 83 (69% ) 130 (76% ) 51 (61% )
missing 7 18 17 0.06
Patient gender
male 50 (39% ) 95 (50% ) 50 (50% )
female 77 (61% ) 95 (50% ) 50 (50% ) 0.14
Donor gender
male 71 (57% ) 115 (61% ) 51 (51% )
female 54 (43% ) 72 (39% ) 48 (49% )
missing 2 3 1 0.26
Patient CMV status
negative 27 (28% ) 74 (40% ) 48 (38% )
positive 71 (72% ) 113 (60% ) 79 (62% )
missing 0 3 2 0.12
Donor CMV status
negative 63 (51% ) 107 (58% ) 47 (47% )
positive 60 (49% ) 79 (42% ) 52 (53% )
missing 4 4 1 0.24
T-cell depletion in-
vivo
no 8 (6% ) 34 (18% ) 88 (88% )
0.001
Median follow-up 
in months (range) 35 (25-45) 2 (20-26) 51 (34-69)
ATG 112 (88% ) 21 (11% ) 11 (11% )
Campath 7 (6% ) 135 (71% ) 1 (1% ) <0.001
ALL-acute lymphoblastic leukemia, ATG-antithymocyte globulin
CMV-cytomegalovirus, TX -transplantation
FLUBU (reference) 1
FLUMEL 1.33 0.85-2.08 0.21
FLUTBI 0.87 0.46-1.66 0.67
Age (per 10 years) 1.56 1.21-2.03 0.0007
Year of Tx 1.01 0.95-1.07 0.87
Time from diagnosis 0.99 0.94-1.06 0.88
UD vs MSD 1.35 0.94-1.93 0.11
Patient female 0.67 0.49-0.93 0.01
Donor female 0.89 0.63-1.24 0.48
Patient CMV positive 0.92 0.64-1.31 0.63
Donor CMV positive 1.31 0.93-1.85 0.12
TCD in-vivo 0.74 0.45-1.23 0.25
centre 0.09
FLUBU (reference) 1
FLUMEL 1.23 0.82-1.85 0.31
FLUTBI 1.06 0.59-1.92 0.85
Age (per 10 years) 1.57 1.23-2.01 0.0003
Year of Tx 0.98 0.93-1.03 0.42
Time from diagnosis 0.99 0.93-1.05 0.74
UD vs MSD 1.05 0.76-1.45 0.78
Patient female 0.82 0.61-1.1 0.19
Donor female 0.88 0.65-1.2 1.43
Patient CMV positive 0.78 0.57-1.08 0.14
Donor CMV positive 1.36 0.99-1.86 0.06
TCD in-vivo 0.91 0.57-1.45 0.69
centre 0.12
FLUBU (reference) 1
FLUMEL 0.96 0.62-1.48 0.86
FLUTBI 1.12 0.59-1.13 0.72
Age (per 10 years) 1.4 1.05-1.87 0.02
Year of Tx 0.98 0.92-1.05 0.57
Time from diagnosis 1.01 0.94-1.08 0.86
UD vs MSD 0.77 0.52-1.13 0.18
Patient female 0.9 0.63-1.27 0.54
Donor female 0.93 0.65-1.34 0.69
Patient CMV positive 0.66 0.45-0.97 0.03
Donor CMV positive 1.43 0.97-2.12 0.07
















FLUMEL 1.97 1.05-3.72 0.04
FLUTBI 0.9 0.36-2.25 0.81
Age (per 10 years) 2.08 1.37-1.52 0.0006
Year of Tx 0.97 0.88-1.06 0.52
Time from diagnosis 0.93 0.84-1.05 0.23
UD vs MSD 2.22 1.23-4.01 0.008
Patient female 0.67 0.41-1.10 0.11
Donor female 0.96 0.57-1.61 0.88
Patient CMV positive 1.16 0.67-2.014 0.59
Donor CMV positive 1.39 0.82-2.34 0.22
TCD in-vivo 0.87 0.43-1.79 0.71
centre 0.27
FLUBU (reference) 1
FLUMEL 1.23 0.86-1.75 0.25
FLUTBI 1.25 0.77-2.02 0.37
Age (per 10 years) 1.53 1.23-1.90 0.0001
Year of Tx 0.98 0.93-1.03 0.41
Time from diagnosis 0.98 0.93-1.03 0.46
UD vs MSD 1.11 0.82-1.50 0.49
Patient female 0.82 0.63-1.06 0.12
Donor female 0.95 0.72-1.25 0.73
Patient CMV positive 0.85 0.64-1.13 0.27
Donor CMV positive 1.03 0.77-1.37 0.86
TCD in-vivo 0.73 0.50-1.07 0.11
centre 0.22
CMV-cytomegalovirus, GVHD-graft.-versus-host disease, MSD-matched sibling donor
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